Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králíčková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL; COMPACT Investigators. Longhurst H, et al. Among authors: lawo jp. N Engl J Med. 2017 Mar 23;376(12):1131-1140. doi: 10.1056/NEJMoa1613627. N Engl J Med. 2017. PMID: 28328347 Free article. Clinical Trial.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. Lumry WR, et al. Among authors: lawo jp. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31. J Allergy Clin Immunol Pract. 2018. PMID: 29391286 Free article. Clinical Trial.
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H; on behalf of the COMPACT Investigators. Lumry WR, et al. Among authors: lawo jp. Orphanet J Rare Dis. 2021 Feb 15;16(1):86. doi: 10.1186/s13023-020-01658-4. Orphanet J Rare Dis. 2021. PMID: 33588897 Free PMC article.
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H; COMPACT Investigators. Lumry WR, et al. Among authors: lawo jp. Orphanet J Rare Dis. 2021 Jul 28;16(1):329. doi: 10.1186/s13023-021-01975-2. Orphanet J Rare Dis. 2021. PMID: 34321052 Free PMC article. No abstract available.
Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, Jacobs I, Lawo JP, Glassman F, Akama H, Hide M, Ohsawa I. Fukuda T, et al. Among authors: lawo jp. Allergol Int. 2023 Jul;72(3):451-457. doi: 10.1016/j.alit.2023.02.002. Epub 2023 Feb 28. Allergol Int. 2023. PMID: 36858856 Free article. Clinical Trial.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Free article. Clinical Trial.
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31355323 Free PMC article. Clinical Trial.
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Léger JM; PRIMA trial investigators. Merkies ISJ, et al. Among authors: lawo jp. J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204. J Peripher Nerv Syst. 2017. PMID: 28594116 Free PMC article. Clinical Trial. No abstract available.
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
Shebl A, Gabriel S, Van Dinther K, Hubsch A, Lawo JP, Hoefferer L, Welsh S. Shebl A, et al. Among authors: lawo jp. Transfusion. 2020 Jun;60(6):1278-1286. doi: 10.1111/trf.15846. Epub 2020 May 14. Transfusion. 2020. PMID: 32410287 Free PMC article.
33 results